A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy

Ann Oncol. 2016 Jan;27(1):199-200. doi: 10.1093/annonc/mdv496. Epub 2015 Oct 20.

Authors

T Grellety¹, I Soubeyran², J Robert³, H Bonnefoi¹, A Italiano⁴

Affiliations

¹ Department of Medical Oncology, Institut Bergonié, Bordeaux.
² Department of Pathology, Institut Bergonié, Bordeaux.
³ INSERM U916, Institut Bergonié, University of Bordeaux, Bordeaux, France.
⁴ Department of Medical Oncology, Institut Bergonié, Bordeaux a.italiano@bordeaux.unicancer.fr.

PMID: 26487584
DOI: 10.1093/annonc/mdv496

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antigens, CD
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / diagnostic imaging*
Breast Neoplasms / drug therapy
Breast Neoplasms / metabolism
Breast Neoplasms / pathology
Cadherins / genetics*
Capecitabine / administration & dosage
Carcinoma, Lobular / diagnostic imaging*
Carcinoma, Lobular / drug therapy
Carcinoma, Lobular / metabolism
Carcinoma, Lobular / secondary
Female
Humans
Lapatinib
Liver Neoplasms / diagnostic imaging*
Liver Neoplasms / drug therapy
Liver Neoplasms / metabolism
Liver Neoplasms / secondary
Middle Aged
Molecular Targeted Therapy
Mutation, Missense
Quinazolines / administration & dosage
Radiography
Receptor, ErbB-2 / genetics*
Treatment Outcome

Substances

Antigens, CD
CDH1 protein, human
Cadherins
Quinazolines
Lapatinib
Capecitabine
ERBB2 protein, human
Receptor, ErbB-2